Melanotan I vs Oligopeptide-1
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Afamelanotide, Scenesse
Melanotan I is the research name for afamelanotide (code CUV1647), a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), also written as [Nle4, D-Phe7]-alpha-MSH or NDP-MSH. Sold as Scenesse, it was approved by the EMA in 2014 and the FDA in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP), one of a few approved melanocortin drugs alongside bremelanotide (Vyleesi) and setmelanotide (Imcivree). The approval covers only the 16 mg bioresorbable implant placed under the skin by a clinician. The injectable 'Melanotan I' sold online is not approved for anything.
Also: sh-Oligopeptide-1, rh-Oligopeptide-1
sh-Oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (EGF), a 53-amino-acid protein your skin uses to tell cells to divide and repair. It shows up in 'EGF serums' aimed at wrinkles, texture and post-procedure recovery. It is a cosmetic ingredient in skincare, not an FDA-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled.
Key Comparison Insights
- Melanotan I is FDA approved, while Oligopeptide-1 remains in research stages.
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- Melanotan I has stronger research evidence (FDA Approved) compared to Oligopeptide-1 (Human Trials).
Detailed Comparison
| Attribute | Melanotan I | Oligopeptide-1 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Afamelanotide binds and activates the melanocortin-1 receptor (MC1R) on pigment-producing melanocytes, driving production of eumelanin, the dark, photoprotective form of melanin. Two amino acid swaps from natural alpha-MSH - norleucine at position 4 and D-phenylalanine at position 7 - make it bind MC1R more tightly and resist breakdown, so it lasts far longer and acts more potently than the native hormone. The extra eumelanin absorbs and scatters light and also brings antioxidant and DNA-repair-supporting effects, which is why it raises the light dose EPP patients can tolerate before pain hits. Unlike Melanotan II, it is selective enough toward MC1R that it is not primarily a sexual-function or appetite agent. | EGF binds the EGF receptor on keratinocytes and fibroblasts and switches on growth and repair signaling: cell division, migration, and production of matrix proteins. That is why it has been studied for wound healing, and why cosmetic brands use it to support skin renewal. Two practical problems: EGF is a fairly large protein, so getting it through intact skin is hard (which is why many studies pair it with microneedling or lasers), and it is fragile, so how much stays active in a jar at room temperature is a fair question. The same growth-promoting signal is also the source of the safety debate: EGF receptor signaling drives several cancers, so the concern is not that EGF causes cancer, but whether it could encourage abnormal cells that are already there. |
| Common Dosing | 500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance) Daily during loading (1-2 weeks), then 1-2x weekly maintenance | Low parts-per-million concentration in a serum Once or twice daily |
| Administration | Subcutaneous implant (not injection) | Topical (serums, ampoules, creams); sometimes combined with microneedling in clinic |
| Typical Duration | Long-term / as needed before sun season | Studies typically ran 4 to 12 weeks |
| Best Time to Take | Before the sunny season (approved implant); evening for unapproved injectables | Evening skincare routine, or right after an in-clinic procedure |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the few peptides on this list with gold-standard human evidence. The pivotal data came from two multicenter, randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2015 (Langendonk et al., 373(1):48-59), enrolling 168 EPP patients across the EU (74) and US (94) who received the 16 mg implant or placebo every 60 days. Afamelanotide significantly increased pain-free time in sunlight (median 69.4 vs 40.8 hours in the US trial; 6.0 vs 0.8 hours in the EU trial, where phototoxic reactions also dropped from 146 to 77), and improved disease-specific quality of life, with mostly mild adverse events. Long-term observational follow-up of EPP patients has supported continued benefit and an acceptable safety profile. Clinuvel is also running a phase 3 vitiligo trial (CUV105), with topline results guided for December 2026. The big caveats: this approval is narrowly for EPP, not for cosmetic tanning, and the unregulated injectable 'Melanotan' products people buy online are not the same controlled, clinician-administered implant and carry real risks. Bottom line: a genuinely proven, approved drug for a rare condition, frequently misused outside that lane. | A 2021 systematic review in the Journal of Cutaneous and Aesthetic Surgery (Miller-Kobisher and colleagues) found 49 articles on rhEGF for skin, including 23 aesthetic studies. Most reported less wrinkling, better hydration and elasticity, and the strongest data were for pigmentation after lasers and melasma. But the authors admit many trials were uncontrolled or not randomized, samples were often 8 to 40 people, and they called for proper controlled trials. Adverse effects were mild and short-lived. The review did not address cancer risk at all, which is a real gap. Several of the better-known growth-factor trials tested multi-factor mixtures, not EGF alone. On safety: there is no human evidence that cosmetic EGF causes skin cancer, and in vitro tests of growth-factor cosmetics on melanoma cells were reassuring, but long-term studies in healthy skin do not exist. Sensible caution: people with a history of skin cancer, many atypical moles, or active psoriasis should talk to a dermatologist before using it. Bottom line: plausible and widely used, modest and mostly low-quality efficacy data, and an unresolved theoretical safety question. |
Frequently Asked Questions: Melanotan I vs Oligopeptide-1
What is the difference between Melanotan I and Oligopeptide-1?
Melanotan I is a skin & hair peptide that melanotan i is the research name for afamelanotide (code cuv1647), a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-msh), also written as [nle4, d-phe7]-alpha-msh or ndp-msh. sold as scenesse, it was approved by the ema in 2014 and the fda in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (epp), one of a few approved melanocortin drugs alongside bremelanotide (vyleesi) and setmelanotide (imcivree). the approval covers only the 16 mg bioresorbable implant placed under the skin by a clinician. the injectable 'melanotan i' sold online is not approved for anything. Oligopeptide-1 is a skin & hair peptide that sh-oligopeptide-1 is the cosmetic ingredient name for recombinant human epidermal growth factor (egf), a 53-amino-acid protein your skin uses to tell cells to divide and repair. it shows up in 'egf serums' aimed at wrinkles, texture and post-procedure recovery. it is a cosmetic ingredient in skincare, not an fda-approved drug for skin aging, and while there are a fair number of small human studies, very few are properly controlled. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Melanotan I or Oligopeptide-1?
Neither is universally "better" - the choice depends on your specific goals. Melanotan I is typically used for skin & hair purposes, while Oligopeptide-1 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Melanotan I and Oligopeptide-1 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Melanotan I and Oligopeptide-1 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.